Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
AKBA
$2.71
Akebia Therapeutics
$.17
6.69%
AKBA
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus: ($0.33)
Revenue: $52.58 Mil
Thursday
Feb 3
8:05 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, November 4, 2021
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
What do you expect when AKBA reports earnings?
Beat
Meet
Miss
Where is AKBA's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$2.77
$2.68
$2.61
$2.52
Support
$2.45
$2.36
$2.29
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Peers
Vertex Pharmaceuticals
Ultragenyx Pharmaceutical
Regeneron Pharmaceuticals
BioMarin Pharmaceutical
Merck & Co.
Zoetis
Eli Lilly
Bristol-Myers Squibb
InterCept
Pfizer
Expectations
›
Akebia Therapeutics
